Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

3097 - Lower Tumor Mutational Burden (TMB) and Hepatic Metastases May Predict for Lack of Response to PD-1 Blockade in MSI-H Metastatic Colorectal Cancer (MCRC)

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Targeted Therapy

Tumour Site

Colon and Rectal Cancer

Presenters

Idoroenyi Amanam

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

I. Amanam1, J. Chao1, D. Lim1, S. Rahmanuddin1, A.B. Schrock2, S.M. Ali3, C. Lau1, D. Chevalier1, E. Harris1, J. Saluja1, C. Wang1, M. Fakih1

Author affiliations

  • 1 Department Of Medical Oncology And Therapeutics, City of Hope, 91010 - Duarte/US
  • 2 Genetics, Foundation Medicine, Inc., MA 02141 - Cambridge/US
  • 3 Genetics, Foundation Medicine, MA 02141 - Cambridge/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3097

Background

MCRC with microsatellite instability (MSI-H) are associated with cytotoxic lymphocytic infiltration that is counterbalanced by multiple checkpoints. Several prospective clinical trials in chemotherapy-resistant MSI-H MCRC have demonstrated a high rate of disease control and a favorable progression free survival (PFS) with PD-1 inhibitors. However, there is a significant discrepancy in response rates (RR) with pembrolizumab and nivolumab (28% to 52%), likely reflecting patient heterogeneity. We sought to determine the RR to PD-1/PD-L1 targeting in a single center setting.

Methods

All MCRC patients (pts) with MSI-H tumors (by CLIA certified PCR, IHC, or NGS assays) who were treated at City of Hope with PD-1 or PD-L1 inhibitors starting Jan 2016 were identified. RR and PFS were determined by RECIST 1.1. BRAF status, primary tumor location, and metastatic sites were collected on all pts. TMB as determined by FoundationOne® on 0.83-1.1 megabases (Mb) of sequenced DNA was collected, when available.

Results

17 pts with MSI-H tumors were identified (16 treated with pembrolizumab and 1 with darvulumab). Pts characteristics were: males (10, 59%), age (median 53.7 years, range 33-78), BRAF mutant (6, 35%), right sided (11, 65%), and liver-sparing (8, 47%). 7 (41%) had an objective response, 2 (12%) had stable disease. The median PFS was 9.97 months (mo), and the 6 and 12 mo PFS rates were 53% and 35%, respectively. TMB was available for 9 MSI-H cases (range 8 – 73 mutations/Mb): 1 CR (TMB 73), 1 PR (TMB 71), and 1 SD (TMB 31), and 6 PD (TMB: 6, 13, 16, 18, 25, 36). We categorized our patients based on the lowest 10% (TMB < 23.5) and 25% (TMB < 33.06) TMB cut points identified from a large Foundation Medicine database of MSI-H MCRC. All 4/4 patients in the lowest TMB decile and 5/6 in the lowest TMB quartile experienced PD. On univariate analysis, only hepatic metastases (p = 0.01) and low TMB (p = 0.02) were associated with poor PFS.

Conclusions

A substantial percentage of pts with MSI-H tumors will progress with PD-1/PD-L1 inhibitors; these patients appear to be enriched for a low TMB status and hepatic metastases. Additional studies should explore TMB as a predictive marker of response to checkpoint inhibition in MSI-H CRC.

Clinical trial identification

Legal entity responsible for the study

City of Hope.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.